Cipla (NSE:CIPLA, BOM:500087) said the U.S. Food and Drug Administration classified an inspection of its manufacturing facility in Verna, Goa, as Voluntary Action Indicated (VAI), according to a Thursday filing on Indian exchanges.
A VAI classification indicates that "objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action," according to the inspection classification available on U.S. FDA website.
The inspection, which included a routine inspection of current Good Manufacturing Practices and a pre-approval inspection, was conducted between April 6 and 17, the filing said.
Shares of the company rose nearly 1% in recent trade.